Armed with a new $6.8 million grant from the U.K.'s Wellcome Trust, Australian scientists are fine-tuning a drug designed to stop cancer patients from rejecting bone marrow transplants. Assuming they proceed on schedule, they hope to start human clinical trials by 2016, Sky News reports.
Merck won a legal victory in Australia in its ongoing litigation over painkiller Vioxx outside of the U.S.
Osprey Medical ($OSP) has reportedly caught the eye of investors with an auspicious beginning in its first day trading on the Australian Securities Exchange (ASX). It made its debut with a 5% premium listing at 42 cents, 2 cents above its issue price, The Australian notes.
Melbourne researchers with the Monash Vision Group, who are on track to have a direct-to-brain bionic eye implant ready for human trials next year, are ready to test its first full system prototype this month.
You've heard about China and India becoming increasingly significant locales in the Asia-Pacific region for conducting biotechnology research and drug development. Australia, not so much.
In an all-stock deal, Australian CRO vivoPharm has acquired RMIT University's Drug Discovery Technologies (RDDT) division.
Australia seems to be an increasingly popular spot for foreign devicemakers to raise funds through initial public offerings and subsequently list on that country's exchange. Following in the footsteps of GI Dynamics, U.S.-based Osprey Medical has raised $20 million Australian in its IPO and plans to list on the Australian Securities Exchange.
It seems that the prolonged whooping cough epidemic that's swept Australia is caused by a new strain that is evading the protection given by the vaccine.
The FDA and EU officials aren't the only global regulators receiving criticism for oversight of medical devices. Australia's Therapeutic Goods Administration is being taken to task for its advice to doctors and patients on device safety. A group of articles in The Medical Journal of Australia assess the TGA's ability to regulate medical devices--and the authors don't give it an A.
Watson Pharmaceuticals ($WPI) expanded its reach in the Asia-Pacific with a deal to buy Strides Arcolab's Australia-based generics business, which is known as Ascent Pharmahealth. The buyout not only